Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
As of Nov 13, 2026, NDA 215206 (Qulipta), held by Abbvie, was first approved by FDA on Sep 28, 2021, with 5 approved supplements and 0 published complete response letters.
First approved: Sep 28, 2021
Review: Priority
Supplements approved: 5
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
QULIPTA is indicated for the preventive treatment of migraine in adults.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
